Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 12 2019
10 12 2019
Historique:
pubmed:
14
9
2019
medline:
17
6
2020
entrez:
14
9
2019
Statut:
ppublish
Résumé
Despite concerns that power morcellation may adversely affect prognosis of patients with occult uterine cancer, empirical evidence has been limited and inconclusive. In this study, we aimed to determine whether uncontained power morcellation at the time of hysterectomy or myomectomy is associated with increased mortality risk in women with occult uterine cancer. By linking statewide hospital discharge records with cancer registry data in New York, we identified 843 women with occult endometrial carcinoma and 334 women with occult uterine sarcoma who underwent a hysterectomy or myomectomy for presumed benign indications during the period October 1, 2003, through December 31, 2013. Within this cohort, we compared disease-specific and all-cause mortality of women who underwent laparoscopic supracervical hysterectomy/laparoscopic myomectomy (LSH/LM), a surrogate indicator for uncontained power morcellation, with women who underwent supracervical abdominal hysterectomy and total abdominal hysterectomy (TAH), which did not involve power morcellation. Multivariable Cox regressions and propensity score method were used to adjust for patient characteristics. Among women with occult uterine sarcoma, LSH/LM was associated with a higher risk for disease-specific mortality than TAH (adjusted hazard ratio [aHR], 2.66, 95% CI, 1.11 to 6.37; adjusted difference in 5-year disease-specific survival, -19.4%, 95% CI, -35.8% to -3.1%). In the subset of women with leiomyosarcoma, LSH/LM was associated with an increased risk for disease-specific mortality compared with supracervical abdominal hysterectomy (aHR, 3.64, 95% CI, 1.50 to 8.86; adjusted difference in 5-year disease-specific survival, -31.2%, 95% CI, -50.0% to -12.3%) and TAH (aHR, 4.66, 95% CI, 1.97 to 11.00; adjusted difference in 5-year disease-specific survival, -37.3%, 95% CI, -54.2% to -20.3%). Among women with occult endometrial carcinoma, there was no significant association between surgical approach and disease-specific mortality. Uncontained power morcellation was associated with higher mortality risk in women with occult uterine sarcoma, especially in those with occult leiomyosarcoma.
Identifiants
pubmed: 31518176
doi: 10.1200/JCO.19.00562
pmc: PMC6901279
doi:
Types de publication
Comparative Study
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3412-3424Subventions
Organisme : AHRQ HHS
ID : R01 HS024702
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
J Minim Invasive Gynecol. 2015 May-Jun;22(4):601-6
pubmed: 25596464
Best Pract Res Clin Obstet Gynaecol. 2018 Jan;46:99-112
pubmed: 29078975
Onco Targets Ther. 2015 Oct 15;8:2943-8
pubmed: 26508879
Am J Obstet Gynecol. 2013 Apr;208(4):277.e1-7
pubmed: 23333543
Obstet Gynecol. 2010 May;115(5):890-1
pubmed: 20410757
Gynecol Oncol. 2014 Feb;132(2):360-5
pubmed: 24296345
BMC Cancer. 2016 Aug 23;16(1):675
pubmed: 27553655
Gynecol Surg. 2015;12(1):3-15
pubmed: 25774118
J Minim Invasive Gynecol. 2014 Jul-Aug;21(4):517-30
pubmed: 24865630
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
BMC Med Res Methodol. 2012 May 30;12:70
pubmed: 22646911
J Natl Cancer Inst. 2002 Jun 5;94(11):835-44
pubmed: 12048271
Arch Gynecol Obstet. 2015 Sep;292(3):665-72
pubmed: 25820974
Womens Health (Lond). 2015 Nov;11(6):929-44
pubmed: 26673851
J Natl Cancer Inst. 2015 Oct 08;107(11):
pubmed: 26449386
Obstet Gynecol. 2019 Mar;133(3):e238-e248
pubmed: 30801477
Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:31-5
pubmed: 26699101
Eur J Obstet Gynecol Reprod Biol. 2018 Jan;220:30-38
pubmed: 29149644
Eur J Obstet Gynecol Reprod Biol. 2019 Jul;238:188-190
pubmed: 31103353
Gynecol Oncol. 2017 Jan;144(1):90-95
pubmed: 27817933
Surg Endosc. 2013 Jul;27(7):2253-7
pubmed: 23660720
J Minim Invasive Gynecol. 2018 May - Jun;25(4):543-550
pubmed: 29581072
Am J Obstet Gynecol. 2019 Jul;221(1):39.e1-39.e14
pubmed: 30853364
Obstet Gynecol. 2018 Aug;132(2):519-520
pubmed: 30045198
J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):963-6
pubmed: 24993657
Gynecol Minim Invasive Ther. 2018 Apr-Jun;7(2):47-55
pubmed: 30254937
Obstet Gynecol. 2016 Jan;127(1):29-39
pubmed: 26646120
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1065-70
pubmed: 17986239
Am J Obstet Gynecol. 2017 Mar;216(3):259.e1-259.e6
pubmed: 27890646
Med Care. 2006 Aug;44(8):745-53
pubmed: 16862036
J Minim Invasive Gynecol. 2015 Feb;22(2):255-60
pubmed: 25460321
Med Care. 2017 Jul;55(7):698-705
pubmed: 28498196
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365
Gynecol Oncol. 2017 Apr;145(1):61-70
pubmed: 28317559